Immunocore is a privately owned, clinical-stage, UK-based biotechnology company, focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease. The Company’s world-leading expertise in engineering T Cell Receptors (TCRs) and linking them to an antibody fragment (scFv) known as anti-CD3, has led to its first product candidate, IMCgp100, entering clinical trials in patients with metastatic melanoma. The proprietary T Cell Receptor technology platform is well validated and can easily be manufactured for clinical and commercial supply in microbial systems.
Type
Private
HQ
Milton, GB
Size (employees)
358 (est)
Immunocore is headquartered in Milton, GB
Report incorrect company information

Key People/Management at Immunocore

Andrew Hotchkiss

Andrew Hotchkiss

Chief Executive Officer/Chief Commercial Officer
Bent Jakobsen

Bent Jakobsen

Chief Scientific Officer
Paul Fry

Paul Fry

Chief Financial Officer
Samantha Pearce

Samantha Pearce

Chief People Officer
Christina Coughlin

Christina Coughlin

Chief Medical Officer
James Sandy

James Sandy

Chief Development Officer

Immunocore Office Locations

Immunocore has an office in Milton
Milton, GB (HQ)
101 Park Dr
Milton, GB (HQ)
101 Park Drive, Milton Park, Abingdon, Oxon
Show all (2)
Report incorrect company information

Immunocore Financials and Metrics

Summary Metrics

Total Funding

$320 m

Latest funding size

$320 m

Time since last funding

3 years ago

Investors

Immunocore's latest funding round in July 2015 was reported to be $320 m. In total, Immunocore has raised $320 m
Show all financial metrics

Immunocore Financials

Immunocore's revenue was reported to be £16.47 m in FY, 2016
GBP

Revenue (FY, 2016)

16.5 m

Net income (FY, 2016)

(40.8 m)

EBITDA (FY, 2016)

(51.7 m)

EBIT (FY, 2016)

(54.4 m)

Cash (31-Dec-2016)

176.6 m
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

2 m6.4 m14.3 m16.5 m

Revenue growth, %

212%

Operating expense total

6.8 m13.7 m(2.9 m)70.9 m

EBITDA

(4.4 m)(7.3 m)18.9 m(51.7 m)
GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

7.2 m3.4 m5 m3.8 m2.3 m16.3 m50.9 m219.7 m176.6 m

Accounts Receivable

1.1 m1.2 m2 m1.6 m307.3 k203 k186 k430 k

Current Assets

7.2 m4.5 m6.1 m5.8 m3.9 m18 m54.3 m228.7 m191.2 m

PP&E

305.2 k493.6 k624.2 k1.1 m1.3 m2.6 m7.8 m11.3 m
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(3.7 m)(5.6 m)16.8 m(40.8 m)

Cash From Operating Activities

11.3 m40.3 m(22.4 m)(38 m)

Cash From Financing Activities

3 m404 k197.7 m96 k

Net Change in Cash

13.8 m34.5 m168.9 m(43.1 m)
GBPY, 2016

Revenue/Employee

102 k

Financial Leverage

1.3 x
Show all financial metrics
Report incorrect company information